Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer John Lunger - Chief Patient Supply Officer Jo Brewer - Chief Scientific Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities Jonathan Chang - Leerink Partners Yanan Zhu - Wells Fargo Securities Operator Hello and welcome to Adaptimmune's Fourth Quarter an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other juris ...

Exhibit 99.1 Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024 Confirmatory evidence for afami-cel full approval agreed with FDA; will use data from Cohort 2 of pivotal SPEARHEAD-1 trial, which is fully enrolled Company is targeting launch of afami-cel upon receipt of FDA approval with commercial, manufacturing, and supply chain teams prepar ...

Adaptimmune Therapeutics (ADAP) is a clinical-stage biopharmaceutical company focused on developing novel T-cell therapies targeting cancer indications.The most advanced candidate in the company’s pipeline is afamitresgene autoleucel (or afami-cel), an engineered T-cell therapy for advanced synovial sarcoma, a malignant tumor that affects the tissue around the joints.Since the past month, shares of Adaptimmunehave soared 83.1% compared with the industry’s 7.0% rise. The upside can be attributed to the compl ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Officer Dennis Williams – Senior Vice President-Late Stage Development Elliot Norry – Chief Medical Officer Jo Brewer – Chief Scientific Officer Gavin Wood – Chief Financial Officer Conference Call Participants Jerry Gong – Mizuho Securities Marc Frahm – TD Cowen Dylan Drakes – Leerink Partners Yanan Zhu – Wells Fargo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or ot ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2023 Results Conference Call August 9, 2023 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Elliot Norry - Chief Medical Officer Gavin Wood - Chief Financial Officer Conference Call Participants Tony Butler - EF Hutton Marc Frahm - TD Cowen Jonathan Chang - Leerink Partners Mara Goldstein - Mizuho Operator Good morning, ladies and gentlemen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other j ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Helen Tayton-Martin - Chief Business & Strategy Officer Joanna Brewer - Chief Scientific Officer John Lunger - Chief Patient Supply Officer Conference Call Participants Marc Frahm - TD Cowen Tony Butler - EF Hutton Operator Hello. Welcome to Adap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other ...